Goserelin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581988

CAS#: 65807-02-5 (free base)

Description: Goserelin is a gonadotropin releasing hormone agonist. Goserelin is used in prostate cancer and breast cancer therapies and also in the treatment of endometriosis.

Chemical Structure

img
Goserelin
CAS# 65807-02-5 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 581988
Name: Goserelin
CAS#: 65807-02-5 (free base)
Chemical Formula: C59H84N18O14
Exact Mass: 1,268.64
Molecular Weight: 1,269.430
Elemental Analysis: C, 55.82; H, 6.67; N, 19.86; O, 17.64

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 65807-02-5 (free base)   145781-92-6 (acetate)  

Synonym: Goserelin; Decapeptide I; Goserelin; ICI 118630; Zoladex; D-Ser(t-Bu)(sup 6)aza-gly(sup 10)-GNRH.

IUPAC/Chemical Name: (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide

InChi Key: BLCLNMBMMGCOAS-URPVMXJPSA-N

InChi Code: 1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

SMILES Code: CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,269.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548740/ PubMed PMID: 31644049.

2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547863/ PubMed PMID: 31643199.

3: Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019 Oct 16. pii: S1470-2045(19)30486-3. doi: 10.1016/S1470-2045(19)30486-3. [Epub ahead of print] PubMed PMID: 31629656.

4: Sa-Nguanraksa D, Krisorakun T, Pongthong W, O-Charoenrat P. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. Mol Clin Oncol. 2019 Nov;11(5):517-522. doi: 10.3892/mco.2019.1913. Epub 2019 Aug 20. PubMed PMID: 31620283; PubMed Central PMCID: PMC6787953.

5: Maguire MJ, Nevitt SJ. Treatments for seizures in catamenial (menstrual-related) epilepsy. Cochrane Database Syst Rev. 2019 Oct 14;10:CD013225. doi: 10.1002/14651858.CD013225.pub2. [Epub ahead of print] Review. PubMed PMID: 31608992.

6: Benetti-Pinto CL, Mira TAA, Yela DA, Teatin-Juliato CR, Brito LGO. Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review. Rev Bras Ginecol Obstet. 2019 Sep;41(9):564-574. doi: 10.1055/s-0039-1695737. Epub 2019 Sep 23. PubMed PMID: 31546278.

7: Lanišnik Rižner T, Penning TM. Aldo-keto reductase 1C3 - assessment as a new target for the treatment of endometriosis. Pharmacol Res. 2019 Sep 20:104446. doi: 10.1016/j.phrs.2019.104446. [Epub ahead of print] Review. PubMed PMID: 31546014.

8: Kim HA, Lee JW, Nam SJ, Park BW, Im SA, Lee ES, Jung YS, Yoon JH, Kang SS, Lee SJ, Park KH, Jeong J, Cho SH, Kim SY, Kim LS, Moon BI, Lee MH, Kim TH, Park C, Jung SH, Gwak G, Kim J, Kang SH, Jin YW, Kim HJ, Han SH, Han W, Hur MH, Noh WC; Korean Breast Cancer Study Group. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. J Clin Oncol. 2019 Sep 16:JCO1900126. doi: 10.1200/JCO.19.00126. [Epub ahead of print] PubMed PMID: 31518174.

9: Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Breast J. 2019 Aug 25. doi: 10.1111/tbj.13516. [Epub ahead of print] PubMed PMID: 31448513.

10: Yip F, Zavery B, Poulter-Clark H, Spencer J. Putting patients first: an inventive service delivering cancer treatment at home. J Comp Eff Res. 2019 Sep;8(12):951-960. doi: 10.2217/cer-2019-0038. Epub 2019 Aug 23. PubMed PMID: 31441319.

11: Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investig Clin Urol. 2019 Jul;60(4):244-250. doi: 10.4111/icu.2019.60.4.244. Epub 2019 May 21. PubMed PMID: 31294133; PubMed Central PMCID: PMC6607074.

12: Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer. Breast J. 2019 Sep;25(5):880-888. doi: 10.1111/tbj.13345. Epub 2019 Jul 9. PubMed PMID: 31290203.

13: Shin MS, Kim TW, Park SS, Ko IG, Kim CJ, Kim M, Roh SY, Kim KT, Kim KH. Long-term Surgical and Chemical Castration Deteriorates Memory Function Through Downregulation of PKA/CREB/BDNF and c-Raf/MEK/ERK Pathways in Hippocampus. Int Neurourol J. 2019 Jun;23(2):116-124. doi: 10.5213/inj.1938103.052. Epub 2019 Jun 30. PubMed PMID: 31260611; PubMed Central PMCID: PMC6606934.

14: Qi P, Bu R, Zhang H, Yin J, Chen J, Zhang A, Gou J, Yin T, Zhang Y, He H, Wang P, Tang X, Wang Y. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System. Mol Pharm. 2019 Aug 5;16(8):3502-3513. doi: 10.1021/acs.molpharmaceut.9b00344. Epub 2019 Jul 10. PubMed PMID: 31251642.

15: Shimada H, Sasaki H, Kasai K, Egawa S. [Gonadotroph Pituitary Adenoma Causing Severe Headache Following Repeated Use of GnRH Agonist for Prostate Cancer]. Hinyokika Kiyo. 2019 May;65(5):171-174. doi: 10.14989/ActaUrolJap_65_5_171. Japanese. PubMed PMID: 31247696.

16: Huang YT, Li CC, Chou YH, Ke HL, Chen CY. Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study. Int J Clin Pharm. 2019 Aug;41(4):993-1003. doi: 10.1007/s11096-019-00854-y. Epub 2019 Jun 25. PubMed PMID: 31240550.

17: Wang SY, Wang S. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Jun 18;51(3):536-541. doi: 10.19723/j.issn.1671-167X.2019.03.024. Chinese. PubMed PMID: 31209428.

18: Røge R, Simonsen C, Petersen AC. Primary Mediastinal Choriocarcinoma in an Elderly Patient with Concurrent Goserelin-Treated Prostate Adenocarcinoma. Case Rep Pathol. 2019 May 6;2019:2734815. doi: 10.1155/2019/2734815. eCollection 2019. PubMed PMID: 31198613; PubMed Central PMCID: PMC6526543.

19: Ma BL, Yao L, Fan Y, Wang Y, Meng YS, Zhang Q, He ZS, Jin J, Zhou LQ. Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer. Cancer Manag Res. 2019 May 10;11:4143-4151. doi: 10.2147/CMAR.S196378. eCollection 2019. PubMed PMID: 31190986; PubMed Central PMCID: PMC6522651.

20: Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4. PubMed PMID: 31166679.